DDrare: Database of Drug Development for Rare Diseases

Searched query = "Inclusion body myositis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ABC008; ARIMOCLOMOL; Alemtuzumab; Alemtuzumab (Campath); Anakinra; Arimoclomol; Arimoclomol citrate; BOTULINUM TOXIN TYPE A; BRX-345; BYM338; BYM338 (Bimagrumab); BYM338/bimagrumab; Bimagrumab; Botulinum toxin type A; Care as usual; Etanercept; FLEBOGAMMA 5%; Gamma Globulin; Immunoglobulins, normal human, for intravascular adm.; Natalizumab; Null; Other: Blood-flow restricted training; Phenylbutyrate; Phenylbutyrate Oral Tablet; Pioglitazone; RAAV1.CMV.huFollistatin344; REGN2477+REGN1033; Rapamycin; SIVASTIN; Simvastatin; Sivastin; Xeomin

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04659031 (ClinicalTrials.gov)	April 2021	25/11/2020	A Phase 1 Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM)	A Phase 1, Open-Label, Ascending Dose Study of ABC008 in Adult Patients With Inclusion	Inclusion Body Myositis	Drug: ABC008	Abcuro, Inc.	NULL	Not yet recruiting	40 Years	N/A	All	39	Phase 1	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04659031
(ClinicalTrials.gov)

April 2021

25/11/2020

A Phase 1 Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM)

A Phase 1, Open-Label, Ascending Dose Study of ABC008 in Adult Patients With Inclusion

Inclusion Body Myositis

Drug: ABC008

Abcuro, Inc.

NULL

Not yet recruiting

40 Years

N/A

All

Phase 1

NULL